Abstract: The present disclosure relates to feedback methods and apparatuses. In one example method, a first communication apparatus may receive first information. The first information includes at least one of channel state information (CSI) measurement quantity indication information for channel variation calculation, a CSI type and a rule that are for the channel variation calculation, or a feedback suggestion parameter. The feedback suggestion parameter indicates a suggested feedback form. The first information is used to select a second communication apparatus. The first communication apparatus may determine, based on the first information, whether to trigger the second communication apparatus/apparatuses to send a feedback result. Correspondingly, the first communication apparatus receives the feedback result.

Abstract: The present invention relates to a process of removing free-unlabeled radionuclides from a radiopharmaceutical prior to administering the radiopharmaceutical to the patient using size-exclusion or ion-exchange mechanisms.

Abstract: This application relates to the field of wireless communication, and in particular, to individually addressed traffic indication methods and apparatuses applicable to multiple links, for example, in a wireless local area network supporting an 802.11be standard. In an example method, a first access point (AP) of a first access point multi-link device (AP MLD) generates and sends individually addressed traffic indication information. The individually addressed traffic indication information is used to indicate whether a non-AP MLD associated with the first AP MLD has a downlink individually addressed traffic and whether a non-AP MLD associated with a second AP MLD has a downlink individually addressed traffic. The second AP MLD is an AP MLD to which a non-transmitted AP belongs. The non-transmitted AP is in a multiple basic service set identifier (BSSID) set in which the first AP is located.

Abstract: The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I wherein T is a SST2R targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.

Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I: T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula I.

Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I: T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula I.

Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I. T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits, and uses of the conjugate of Formula I.

Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).

Abstract: A method of performing a chelating reaction comprising contacting a divalent metal with a compound of Formula (I): or a salt thereof wherein: each of R1-R4 is independently selected from the group consisting of CH2COORa and CH2C(?O)NHRa; each of R5-R12 is independently selected from the group consisting of H and -L-X; each Ra is independently selected from the group consisting of H and -L-X; each L is independently selected from the group consisting of absent and a linking group; and each X is a biological agent; and wherein the contacting occurs at a temperature below about 40° C. to form a chelated composition.

Abstract: This disclosure relates to methods and systems for dynamically partitioning of PCIe disk arrays based on software configuration/policy distribution. In one embodiment, at least one PCIe switch has an input port operatively connected to a respective CPU and at least one output port. A multiplexer is connected between the output port(s) of the at least one PCIe switch and a PCIe disk array, for example an NVMe SSD, and is configured to connect the PCIe disk array in a first configuration to a single PCIe switch in either one-x4 port or two x2 port mode, or in a second configuration to two PCIe switches in x2 port mode. The multiplexer can dynamically switch between the first configuration and the second configuration on the fly. Switching can occur, for example, in response to a hot-swap of an NVMe SSD or a policy change.

Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).

Abstract: This disclosure relates to methods and systems for dynamically partitioning of PCIe disk arrays based on software configuration/policy distribution. In one embodiment, at least one PCIe switch has an input port operatively connected to a respective CPU and at least one output port. A multiplexer is connected between the output port(s) of the at least one PCIe switch and a PCIe disk array, for example an NVMe SSD, and is configured to connect the PCIe disk array in a first configuration to a single PCIe switch in either one-x4 port or two x2 port mode, or in a second configuration to two PCIe switches in x2 port mode. The multiplexer can dynamically switch between the first configuration and the second configuration on the fly. Switching can occur, for example, in response to a hot-swap of an NVMe SSD or a policy change.